Abstract
Impaired mitophagy is one of the hallmarks of the pathogenesis of Parkinson’s disease, which highlights the importance of the proper functioning of mitochondria, as well as the processes of mitochondrial dynamics for the functioning of dopaminergic neurons. At the same time, the main factors leading to disruption of mitophagy in Parkinson’s disease are mutations in the Pink1 and Parkin enzymes. Based on the characterized mutant forms, the marked cellular localization, and the level of expression in neurons, these proteins can be considered promising targets for the development of drugs for Parkinson’s therapy. This review will consider such class of drug compounds as mitophagy activators and these drugs in the treatment of Parkinson’s disease.
Funder
Russian Science Foundation
Reference59 articles.
1. (2021, April 10). What Is Parkinson’s? Date Views. Available online: www.parkinson.org/understanding-parkinsons/what-is-parkinsons.
2. Stoker, T.B., and Greenland, J.C. (2018). Parkinson’s Disease: Pathogenesis and Clinical Aspects, Codon Publications. Chapter 1.
3. Prevalence, incidence, and mortality of PD: A door-to-door survey in Ilan County, Taiwan;Neurology,2001
4. Michael, J., Aminoff, R., and Daroff, B. (2014). Encyclopedia of the Neurological Sciences, Academic Press. [2nd ed.].
5. Parkinson’s disease;Lancet,2009
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献